Patients who recently experienced an MI and had an ejection fraction of 35% or less who used a wearable cardioverter-defibrillator had no decreased risk of arrhythmic death, compared with people who did not use a wearable cardioverter-defibrillator, according to an analysis of data from the multicenter, randomized, and controlled VEST trial (NCT01446965). The results were published Sept. 26 in the New England Journal of Medicine (doi: 10.1056/NEJMoa1800781).
We covered this story before it was published in the journal. Find our conference coverage at the links below.